Drug · CHEMBL174
AMPICILLIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. AMPICILLIN. Drugs and targets, record CHEMBL174. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL174
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Amcill, Amfipen, Ampicillin trihydrate, Ampilar, Britcin, Omnipen (ampicillin), Penbritin, Pfizerpen-a, Polycillin, Principen, Principen '125', Principen '250', Principen '500', Totacillin, Vidopen
- ChEMBL
- Other names
AY-6108, Alpha-aminobenzylpenicillin, Aminobenzylpenicillin, Aminobenzylpenicillin trihydrate, Ampicilina, Ampicillin (anhydrous), Ampicillin anhydrous, Ampicillin hydrate, Ampicillin, anhydrous, Ampicillin/ampicillin trihydrate, Ampicilline, Ampicillinum, Anhydrous ampicillin, BRL-1341, NSC-528986, P-50, Poly-cillin, Polycillin-prb, Probampacin, Redicilin, Semicillin, Tokiocillin, Ultrabion, WY 5103
- ChEMBL
- Open Targets' highest stage
- Approval, for 5 of its 15 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases15
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 15Source Open Targets
See all 15 diseasesTrials54
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01994993 | Antibiotic Safety (SCAMP) | Phase 2/3 | 260 | 2018-02-27 | ampicillin | Its name | ClinicalTrials.gov |
| NCT00462020 | Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis | 102 | 2011-12-13 | ampicillin/clavulanic acid | A combination that names it | ClinicalTrials.gov | |
| NCT05977868 | Comparing Oral Versus Parenteral Antimicrobial Therapy | Phase 4 | 94 | 2025-08-26 | ampicillin | Its name | ClinicalTrials.gov |
| NCT00879190 | Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis | Phase 2/3 | 92 | 2017-03-15 | ampicillin | Its name | ClinicalTrials.gov |
| NCT01585129 | Treatment Utility of Postpartum Antibiotics in Chorioamnionitis | Phase 4 | 80 | 2018-05-22 | ampicillin | Its name | ClinicalTrials.gov |
| NCT01561703 | Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use | 58 | 2017-01-19 | ampicillin | Its name | ClinicalTrials.gov | |
| NCT01189487 | The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP) | Phase 3 | 47 | 2012-05-18 | ampicillin | Its name | ClinicalTrials.gov |
| NCT02477423 | A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome | 27 | 2020-09-03 | ampicillin | Its name | ClinicalTrials.gov | |
| NCT02424734 | Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis | Phase 2 | 11 | 2018-07-17 | ampicillin | Its name | ClinicalTrials.gov |
| NCT03795194 | Antibiotic Duration in Post-appendectomy Abscess | Phase 4 | 7 | 2024-03-08 | ampicillin/clavulanate | A combination that names it | ClinicalTrials.gov |
1 to 10 of 54
See all 54 trialsComparisons in its trials27
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| IV Only vs IV and Oral Abx: deaths from any cause | 0 of 52 | 0 of 50 | 102 | NCT00462020 | Trial comparisons |
| IV Only vs IV and Oral Abx: serious adverse events | 0 of 52 | 0 of 50 | 102 | NCT00462020 | Trial comparisons |
| Experimental vs Control: deaths from any cause | 1 of 64 | 0 of 30 | 94 | NCT05977868 | Trial comparisons |
| Experimental vs Control: serious adverse events | 18 of 64 | 7 of 30 | 94 | NCT05977868 | Trial comparisons |
| Unasyn (Ampicillin/Sulbactam) vs Ampicillin/Gentamicin: Composite Maternal Morbidity | 0 of 43 | 6 of 49 | 92 | NCT00879190 | Trial comparisons |
| Unasyn (Ampicillin/Sulbactam) vs Ampicillin/Gentamicin: Treatment Success Defined as Resolution of Fever by 24 Hours Postpartum | 43 of 43 | 49 of 49 | 92 | NCT00879190 | Trial comparisons |
| Unasyn (Ampicillin/Sulbactam) vs Ampicillin/Gentamicin: serious adverse events | 0 of 43 | 0 of 49 | 92 | NCT00879190 | Trial comparisons |
| Group 1 (Experimental) vs Group 2 (Control): Adverse Events Related to Antimicrobial Therapy | 4 of 62 | 4 of 28 | 90 | NCT05977868 | Trial comparisons |
| Group 1 (Experimental) vs Group 2 (Control): Overall Readmission | 17 of 62 | 7 of 28 | 90 | NCT05977868 | Trial comparisons |
| Group 1 (Experimental) vs Group 2 (Control): Cure/Control at 3 Months | 61 of 62 | 28 of 28 | 90 | NCT05977868 | Trial comparisons |
1 to 10 of 27
See all 27 comparisons in its trialsPapers from its trials54
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL174
GET https://conductscience.org/api/drugs/v1/CHEMBL174/trials?page=2